Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the effect of metformin on myocardial function, insulin
resistance and selected metabolic markers in patients with type 2 diabetes and heart failure
(HF+DM+) in a cross-over, randomized, placebo controlled trial.
Hypothesis:
Metformin treatment in HF+DM+ group will lead to better myocardial function and load
tolerance in comparison to placebo. The degree of improvement will be linked to selected
metabolic parameters.